Additionally, treatment of CLL patients with venetoclax and obinutuzumab not only led to eradication of the CLL, but also to reduced Tregs, Tfh and PD-1 expression on CD8+ T-cells, indicating a reversion of T-cell dysfunction and recovery of T-cell skewing [104]. Here, CD8A is linked to B-cell chronic lymphocytic leukemia.